ValiRx PLC Successful 1st Results from VAL201 Clinical Trial (6585F)
February 24 2015 - 1:01AM
UK Regulatory
TIDMVAL
RNS Number : 6585F
ValiRx PLC
24 February 2015
24 February 2015
ValiRx Plc
("ValiRx" or "the Company")
ValiRx reports on successful first results from a
Phase I/II Clinical Trial of VAL201 in patients with cancer
ValiRx Plc (AIM: VAL), the life science company with a focus on
cancer diagnostics and therapeutics for personalised medicine, is
pleased to announce that its lead compound, VAL201 was safe and
well tolerated at the doses tested.
With this result, the trial will advance to the next elevation
of dose, where further safety and tolerability testing will be
undertaken and early stage efficacy will continue to be
investigated as the trial progresses. The trial is directed towards
providing information on the maximum applicable dose level
possible.
The clinical trial is a dose escalation study to assess the
safety and tolerability of VAL201 in patients with locally advanced
or metastatic prostate cancer and other advanced solid tumours.
In addition, ValiRx is pleased that its newly acquired TRAC
biomarker diagnostic and development technology is now fully
established in ValiFinn's clinical labs.
Dr Satu Vainikka, CEO of ValiRx, commented:"This first result
from the clinical trial of the ValiRx compound VAL201 demonstrates
a good safety profile and I am pleased to see the study
successfully progressing well."
Webcast Presentation
A webcast interview by Dr George Morris, COO of ValiRx on the
successful first results from the VAL201 Clinical Trial is
available at 09:00 today by clicking on the following link:
http://brrmedia.co.uk/event/135292?popup=true
About the Phase I/11 Clinical Trial
The main objectives of the Phase I/II study are to confirm
safety and tolerability. Progressing through the dose escalation
and expansion stages, the study is then designed to investigate
further details of these aspects as well as efficacy. Particular
emphasis will be placed on evaluating the pharmacokinetics,
pharmacodynamics and early assessment of anti-tumour activity in
response to VAL201, using a variety of measurements including
ValiRx's biomarkers, with biomarkers being key indicators in
personal medicine. Biomarkers are critical, firstly in identifying
which individuals and which cancers can be helped, before then
being used in the monitoring of those patients for therapeutic
effectiveness. Finally, they significantly assist in the accurate
prediction for and long-term prognosis of patients.
VAL201 selectively prevents tumour growth by specifically
inhibiting the proliferation of tumour cells. As a result, tumour
growth is suppressed and metastasis is significantly reduced. The
approach is a targeted therapeutic with pre-clinical results that
indicate that due to the specific nature of this treatment, this
therapy is likely to be less toxic than many other therapeutic
options.
The VAL201 target is also associated with other cancers and
there is significant potential for VAL201 to be used as a treatment
for other hormone-induced cancers, such as breast and ovarian and
also endometriosis.
The global market for prostate cancer products looks set to
expand to $7-9 billion by 2020, due to the growing prostate cancer
population, which is predicted to expand by 25% from 2010 to 2020
(GlobalData 2012) with many of the other potential indications also
expanding at rapid rates.
Details of the trial can be found on clinicaltrials.gov, where
they are posted as a legal requirement and part of the extensive
work required to reach this stage of human testing in the clinical
development of VAL201.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
Dr Satu Vainikka www.valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7148 7900
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc Tel: +44 (0) 20
(Broker) 7776 6550
Martin Lampshire
Peckwater PR Tel: +44 (0) 7879
458 364
Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk
Notes for Editors
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel
technologies and products in oncology therapeutics and diagnostics.
The product focus is in the epigenomic analysis and treatment of
cancer, but the technologies can be applied to other fields as
well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a
portfolio of innovative products through investment in specific
development projects. It actively manages projects within this
portfolio as a trading company and is not an investment vehicle.
The ValiRx business model spreads the risks of life science
technology developments by minimising financial exposure and
running a set of projects to defined commercial endpoints. This
maximises returns to shareholders by adding value at the earlier
stages where value increases per investment unit are the
greatest.
The Company operates through the following divisional
companies:
1. ValiFinn is the biomarkers and diagnostic development
division
2. ValiPharma is the therapeutics division with two embedded
technologies primarily directed at the treatment of cancers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEANADAELSEFF
Valirx (LSE:VAL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Aug 2023 to Aug 2024